Trials / Completed
CompletedNCT01188863
Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus
A Phase 1, Randomized, Open-Label, Three-Way Crossover Study of Two Oral Formulations of LX4211 in Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Lexicon Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 300 mg LX4211 (150 mg tablets) | Single oral dose of two 150 mg tablets LX4211 |
| DRUG | 300 mg LX4211 (50 mg tablets) | Single oral dose of six 50 mg tablets LX4211 |
| DRUG | 300 mg LX4211 (liquid) | Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL) |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2010-10-01
- First posted
- 2010-08-26
- Last updated
- 2011-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01188863. Inclusion in this directory is not an endorsement.